Safety profile of perindopril

American Journal of Cardiology

Volumn 88, Issue 7, 2001, Pages 36-40

  Clark, Luther T ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMFENAC; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENFLURAMINE; HYDROCHLOROTHIAZIDE; MIBEFRADIL; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC NITRATE; PERINDOPRIL; PERINDOPRILAT; TERFENADINE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIABETES CONTROL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GROUPS BY AGE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

EID: 0035478268     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01920-8     Document Type: Article

References (34)

1. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the Health Examination Surveys, 1960-1991
2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
3. Detection and control of high blood pressure in the community: Do we need a wake-up call?
4. Risk stratification in hypertension: New insights from the Framingham Study
5. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study
6. Should calcium antagonists be first line drugs in hypertension?
7. The calcium channel blocker controversy in perspective
8. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
9. Evidence-based medicine and ACE inhibition
10. Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders
11. EUROPA substudies, confirmation of pathophysiological concepts
12. Blood pressure lowering for the secondary prevention of stroke: Rationale and design for PROGRESS
13. The safety and acceptability of perindopril
14. Cough with angiotensin converting enzyme inhibitors: How much of a problem?
15. The safety of newly approved medicines: Do recent market removals mean there is a problem?
16. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs
17. Perindopril postmarketing surveillance: A 12 month study in 47,351 hypertensive patients
18. Angiotensin-converting enzyme inhibitors in heart failure: Blood pressure changes after the first dose
19. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: A Malaysian experience
20. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: A comparison of enalapril and perindopril
21. Hyperlipidemia of diuretic therapy
22. Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction
23. Treatment of hypertension in the elderly
24. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients
25. Perindopril treatment for congestive heart failure
26. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure
27. Long-term tolerance of perindopril in hypertensive patients with impaired renal function
28. Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy
29. A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies
30. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases
31. Perindopril safety and tolerance in at-risk patients
32. Overview of the angiotensin-converting-enzyme inhibitors
33. Drug interactions in hypertensive patients: Pharmacokinetic, pharmacodynamic and genetic considerations
34. Potential adverse effects of antihypertensive drugs in the elderly